Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study
Objectives To clarify non-alcoholic fatty liver disease (NAFLD) prevalence, risk factors and clinical outcome in an exemplary Chinese population, a cohort of company employees was followed up for 11 years.Design Retrospective cohort study.Setting Between 2006 and 2016 in Ning bo, China.Participants...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-06-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/12/6/e054891.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832584059552792576 |
|---|---|
| author | Steven Dooley Juan Du Xiaoping Tang Lan Chen Jinzhu Jia Fujun Li Yanyan Shi Christoph Meyer Zhongwei Zhu Yanming Zhang Roman Liebe Keming Hu Tingting Zhou Huier Zhang Hong-Lei Weng Tong Huang |
| author_facet | Steven Dooley Juan Du Xiaoping Tang Lan Chen Jinzhu Jia Fujun Li Yanyan Shi Christoph Meyer Zhongwei Zhu Yanming Zhang Roman Liebe Keming Hu Tingting Zhou Huier Zhang Hong-Lei Weng Tong Huang |
| author_sort | Steven Dooley |
| collection | DOAJ |
| description | Objectives To clarify non-alcoholic fatty liver disease (NAFLD) prevalence, risk factors and clinical outcome in an exemplary Chinese population, a cohort of company employees was followed up for 11 years.Design Retrospective cohort study.Setting Between 2006 and 2016 in Ning bo, China.Participants 13 032 company employees.Results Over 11 years, the prevalence of NAFLD increased from 17.2% to 32.4% (men 20.5%–37% vs women 9.8%–22.2%). Male peak prevalence was between 40 and 60 years of age, whereas highest prevalence in women was at an age of 60 years and older. Logistic and Cox regression revealed 16 risk factors, including body mass index (BMI), albumin, white blood cell, triglycerides (TG), high-density lipoprotein, glutamyl transpeptidase, alanine transaminase, creatinine, urea acid, glucose, systolic blood pressure, diastolic blood pressure, blood sedimentation, haemoglobin, platelet and apolipoprotein B2 (p<0.05 for all factors). The area under the curve of these variables for NAFLD is 0.88. However, cause-effect analyses showed that only BMI, gender and TG directly contributed to NAFLD development. Over an 11-year follow-up period, 12.6%, 37.7% and 14.2% of male patients with NAFLD and 11.6%, 44.7% and 22.6% of female patients with NAFLD developed diabetes, hypertension and hyperuricaemia, respectively. Except one male patient who developed cirrhosis, no patients with NAFLD progressed into severe liver disease.Conclusion Diabetes, hypertension and hyperuricaemia are the main clinical outcomes of NAFLD. Eleven years of NAFLD are not sufficient to cause severe liver disease. Age and obesity are direct risk factors for NAFLD. BMI, gender and TG are three parameters directly reflecting the occurrence of NAFLD. |
| format | Article |
| id | doaj-art-3e2b16c24f3b4a99b6c367be56325bc5 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2022-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-3e2b16c24f3b4a99b6c367be56325bc52025-01-27T19:50:10ZengBMJ Publishing GroupBMJ Open2044-60552022-06-0112610.1136/bmjopen-2021-054891Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up studySteven Dooley0Juan Du1Xiaoping Tang2Lan Chen3Jinzhu Jia4Fujun Li5Yanyan Shi6Christoph Meyer7Zhongwei Zhu8Yanming Zhang9Roman Liebe10Keming Hu11Tingting Zhou12Huier Zhang13Hong-Lei Weng14Tong Huang15Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany7 Guangzhou Regenerative Medicine and Health-Guangdong Laboratory (GRMH-GDL), Guangzhou, Guangdong, ChinaDepartment of Prevention and Health Care, Ningbo Zhenhai District Lianhua Hospital, Ningbo, Zhejiang, China3 Department of Internal Medicine, Dongfang People`s Hospital, Dongfang, Hainan, ChinaSchool of Public Health and Center for Statistical Science, Peking University, Beijing, People`s Republic of ChinaDepartment of Radiology, Ningbo Zhenhai District Lianhua Hospital, Ningbo, Zhejiang, ChinaResearch Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China1 Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, GermanyDepartment of Surgery, Ningbo Zhenhai District Lianhua Hospital, Ningbo, Zhejiang, ChinaCenter Laboratory, Ningbo Zhenhai District Lianhua Hospital, Ningbo, Zhejiang, ChinaClinic of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke-University, Magdeburg, GermanyDepartment of Prevention and Health Care, Ningbo Zhenhai District Lianhua Hospital, Ningbo, Zhejiang, ChinaFudan University School of Nursing, Shanghai, ChinaCenter Laboratory, Ningbo Zhenhai District Lianhua Hospital, Ningbo, Zhejiang, ChinaDepartment of Medicine II, Section Molecular Hepatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Baden-Württemberg, GermanyDepartment of Prevention and Health Care, Ningbo Zhenhai District Lianhua Hospital, Ningbo, Zhejiang, ChinaObjectives To clarify non-alcoholic fatty liver disease (NAFLD) prevalence, risk factors and clinical outcome in an exemplary Chinese population, a cohort of company employees was followed up for 11 years.Design Retrospective cohort study.Setting Between 2006 and 2016 in Ning bo, China.Participants 13 032 company employees.Results Over 11 years, the prevalence of NAFLD increased from 17.2% to 32.4% (men 20.5%–37% vs women 9.8%–22.2%). Male peak prevalence was between 40 and 60 years of age, whereas highest prevalence in women was at an age of 60 years and older. Logistic and Cox regression revealed 16 risk factors, including body mass index (BMI), albumin, white blood cell, triglycerides (TG), high-density lipoprotein, glutamyl transpeptidase, alanine transaminase, creatinine, urea acid, glucose, systolic blood pressure, diastolic blood pressure, blood sedimentation, haemoglobin, platelet and apolipoprotein B2 (p<0.05 for all factors). The area under the curve of these variables for NAFLD is 0.88. However, cause-effect analyses showed that only BMI, gender and TG directly contributed to NAFLD development. Over an 11-year follow-up period, 12.6%, 37.7% and 14.2% of male patients with NAFLD and 11.6%, 44.7% and 22.6% of female patients with NAFLD developed diabetes, hypertension and hyperuricaemia, respectively. Except one male patient who developed cirrhosis, no patients with NAFLD progressed into severe liver disease.Conclusion Diabetes, hypertension and hyperuricaemia are the main clinical outcomes of NAFLD. Eleven years of NAFLD are not sufficient to cause severe liver disease. Age and obesity are direct risk factors for NAFLD. BMI, gender and TG are three parameters directly reflecting the occurrence of NAFLD.https://bmjopen.bmj.com/content/12/6/e054891.full |
| spellingShingle | Steven Dooley Juan Du Xiaoping Tang Lan Chen Jinzhu Jia Fujun Li Yanyan Shi Christoph Meyer Zhongwei Zhu Yanming Zhang Roman Liebe Keming Hu Tingting Zhou Huier Zhang Hong-Lei Weng Tong Huang Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study BMJ Open |
| title | Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study |
| title_full | Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study |
| title_fullStr | Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study |
| title_full_unstemmed | Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study |
| title_short | Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study |
| title_sort | clinical outcome of non alcoholic fatty liver disease an 11 year follow up study |
| url | https://bmjopen.bmj.com/content/12/6/e054891.full |
| work_keys_str_mv | AT stevendooley clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy AT juandu clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy AT xiaopingtang clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy AT lanchen clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy AT jinzhujia clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy AT fujunli clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy AT yanyanshi clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy AT christophmeyer clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy AT zhongweizhu clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy AT yanmingzhang clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy AT romanliebe clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy AT keminghu clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy AT tingtingzhou clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy AT huierzhang clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy AT hongleiweng clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy AT tonghuang clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy |